S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda

Horizon Therapeutics Public (HZNP) Short Interest Ratio & Short Volume

Notice: This company has been marked as potentially delisted and may not be actively trading.

Horizon Therapeutics Public Short Interest Data

Current Short Volume
7,100,000 shares
Previous Short Volume
9,480,000 shares
Change Vs. Previous Month
-25.11%
Dollar Volume Sold Short
$818.70 million
Short Interest Ratio / Days to Cover
3.2
Last Record Date
September 15, 2023
Outstanding Shares
228,990,000 shares
Percentage of Shares Shorted
3.10%
Today's Trading Volume
0 shares
Average Trading Volume
2,498,525 shares
Today's Volume Vs. Average
0%
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Horizon Therapeutics Public ?

Sign up to receive the latest short interest report for Horizon Therapeutics Public and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

HZNP Short Interest Over Time

HZNP Days to Cover Over Time

HZNP Percentage of Float Shorted Over Time

Horizon Therapeutics Public Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
9/15/20237,100,000 shares $818.70 million -25.1%N/A3.2 $115.31
8/31/20239,480,000 shares $1.07 billion +20.6%N/A4.1 $112.74
8/15/20237,860,000 shares $818.15 million -7.8%3.5%4.9 $104.09
7/31/20238,520,000 shares $854.30 million +28.1%3.8%3.8 $100.27
7/15/20236,650,000 shares $691.20 million +3.7%3.0%3 $103.94
6/30/20236,410,000 shares $659.27 million -8.2%N/A2.9 $102.85
6/15/20236,980,000 shares $707.14 million -4.0%N/A3.1 $101.31
5/31/20237,270,000 shares $727.22 million +4.6%N/A3.3 $100.03
5/15/20236,950,000 shares $780.14 million +5.8%N/A3 $112.25
4/30/20236,570,000 shares $730.32 million +67.2%N/A3.9 $111.16
4/15/20233,930,000 shares $438.59 million +4.2%N/A1.8 $111.60
3/31/20233,770,000 shares $411.46 million -6.7%N/A1.7 $109.14
3/15/20234,040,000 shares $442.26 million +23.9%N/A1.6 $109.47
2/28/20233,260,000 shares $356.94 million -3.3%N/A0.9 $109.49
2/15/20233,370,000 shares $369.62 million -1.5%N/A0.9 $109.68
1/31/20233,420,000 shares $375.24 million -37.0%1.5%0.8 $109.72
1/15/20235,430,000 shares $614.89 million -12.7%2.4%1.4 $113.24
12/30/20226,220,000 shares $707.84 million -6.6%2.8%1.6 $113.80
12/15/20226,660,000 shares $752.58 million +2.6%3.0%1.7 $113.00
11/30/20226,490,000 shares $650.88 million -7.2%2.9%2.2 $100.29
11/15/20226,990,000 shares $531.59 million -7.1%3.1%2.7 $76.05
10/31/20227,520,000 shares $468.65 million -11.1%3.4%2.7 $62.32
10/15/20228,460,000 shares $528.83 million +4.7%N/A2.8 $62.51
9/30/20228,080,000 shares $500.07 million +43.8%N/A2.8 $61.89
9/15/20225,620,000 shares $357.09 million +21.4%N/A2 $63.54
8/31/20224,630,000 shares $274.14 million -24.6%N/A1.8 $59.21
8/15/20226,140,000 shares $398.49 million -18.6%N/A2.4 $64.90
7/31/20227,540,000 shares $625.59 million +1.6%3.4%3.1 $82.97
7/15/20227,420,000 shares $612.37 million -1.1%3.3%3.7 $82.53
6/30/20227,500,000 shares $598.20 million +7.5%4.5%3.7 $79.76
6/15/20226,980,000 shares $575.64 million +7.6%4.2%3.5 $82.47
5/31/20226,490,000 shares $582.09 million -11.7%2.9%3.5 $89.69
5/15/20227,350,000 shares $664.66 million +20.3%3.3%3.9 $90.43
4/30/20226,110,000 shares $602.20 million -3.9%2.7%3.2 $98.56
4/15/20226,360,000 shares $740.05 million +6.0%2.8%3.7 $116.36
3/31/20226,000,000 shares $631.26 million +5.8%2.7%3.4 $105.21
3/15/20225,670,000 shares $585.48 million +13.9%2.5%3.5 $103.26
2/28/20224,980,000 shares $454.03 million -3.1%2.2%3 $91.17
2/15/20225,140,000 shares $504.59 million +40.4%2.3%3.2 $98.17
1/31/20223,660,000 shares $341.59 million -8.5%1.7%2.5 $93.33
“More countries ditch the US dollar” (Ad)

Since March 2018, China started purchasing oil in gold-backed yuan. By December 2022, Foreign Minister Wang Yi stated that Chinese-Arab relations experienced a "historic improvement." after arab nations ditched the dollar to trade with China. On June 6, 2023 China told its banks to slash interest rates on US dollars.

Get all the details here.

HZNP Short Interest - Frequently Asked Questions

What is Horizon Therapeutics Public's current short interest?

Short interest is the volume of Horizon Therapeutics Public shares that have been sold short but have not yet been covered or closed out. As of September 15th, traders have sold 7,100,000 shares of HZNP short. Learn More on Horizon Therapeutics Public's current short interest.

What is a good short interest ratio for Horizon Therapeutics Public?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. HZNP shares currently have a short interest ratio of 3.0. Learn More on Horizon Therapeutics Public's short interest ratio.

Which institutional investors are shorting Horizon Therapeutics Public?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Horizon Therapeutics Public: Nomura Holdings Inc., GTS Securities LLC, Westchester Capital Management LLC, Prelude Capital Management LLC, Parallax Volatility Advisers L.P., Glazer Capital LLC, HAP Trading LLC, Citadel Advisors LLC, Clear Street Markets LLC, P Schoenfeld Asset Management LP, Balyasny Asset Management L.P., Nomura Holdings Inc., Verition Fund Management LLC, PSquared Asset Management AG, Bardin Hill Management Partners LP, PEAK6 Investments LLC, BTG Pactual Global Asset Management Ltd, Capstone Investment Advisors LLC, Highbridge Capital Management LLC, Concourse Financial Group Securities Inc., Picton Mahoney Asset Management, BCK Capital Management LP, Simplex Trading LLC, and Equitec Proprietary Markets LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Horizon Therapeutics Public's short interest increasing or decreasing?

Horizon Therapeutics Public saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 7,100,000 shares, a drop of 25.1% from the previous total of 9,480,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Horizon Therapeutics Public's short interest compare to its competitors?

Here is how the short interest of companies compare to Horizon Therapeutics Public: Royalty Pharma plc (3.27%), Jazz Pharmaceuticals plc (5.41%), Mirati Therapeutics, Inc. (6.26%), Zoetis Inc. (0.80%), Bristol-Myers Squibb (1.73%), Genmab A/S (0.37%), Alnylam Pharmaceuticals, Inc. (2.22%), BioMarin Pharmaceutical Inc. (1.62%), Teva Pharmaceutical Industries Limited (1.03%), Viatris Inc. (3.14%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($8.05 billion), T-Mobile US, Inc. ($3.94 billion), Charter Communications, Inc. ($3.77 billion), Occidental Petroleum Co. ($3.27 billion), Tractor Supply ($2.29 billion), Celsius Holdings, Inc. ($2.20 billion), Rivian Automotive, Inc. ($2.10 billion), Moderna, Inc. ($2.08 billion), Royal Caribbean Cruises Ltd. ($1.90 billion), and T. Rowe Price Group, Inc. ($1.90 billion). View all of the most shorted stocks.

What does it mean to sell short Horizon Therapeutics Public stock?

Short selling HZNP is an investing strategy that aims to generate trading profit from Horizon Therapeutics Public as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Horizon Therapeutics Public?

A short squeeze for Horizon Therapeutics Public occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of HZNP, which in turn drives the price of the stock up even further.

How often is Horizon Therapeutics Public's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including HZNP, twice per month. The most recent reporting period available is September, 15 2023.



More Short Interest Resources from MarketBeat

This page (NASDAQ:HZNP) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners